The company's Intrathecal Therapy business markets products used in the treatment of spasticity via intrathecal drug delivery, including the key asset Gablofen
The key asset is Gablofen
(baclofen injection), a product approved by the US Food and Drug Administration for use in management of severe spasticity of cerebral or spinal origin in adult and pediatric patients age 4 years and above.
The acquired products include drugs such as Gablofen
for treatment of severe spasticity and two pain management drugs under development.
Tenders are invited for gablofen
500mcg/ml ndc#45945-155-02 or equal.
Food and Drug Administration has approved Covidien plc's Gablofen
prefilled syringe was created to reduce preparation steps, helping to simplify the pump refill process for patients receiving ITB Therapy(SM) (Intrathecal Baclofen Therapy) to treat severe spasticity of cerebral and spinal origin.
According to the company, the Intrathecal Therapy business markets products for the treatment of spasticity via intrathecal drug delivery, including the key asset Gablofen
, CNS Therapeutics is driving the industry ahead by developing new options to improve the management of debilitating neurological conditions.
Included in the acquired portfolio is Gablofen
(baclofen), a severe spasticity management drug that is currently marketed in the US.
The remaining total consideration of up to USD32m is contingent, based on the gross profit of the Gablofen
products in 2018 and 2019.
Included in the portfolio is Gablofen
(baclofen) -- a severe spasticity management product currently marketed in the US - and two pain management products that are under development.
M2 PHARMA-January 22, 2013-Mallinckrodt's new Gablofen
prefilled syringe wins FDA approval to help simplify ITB refills in spastic patients(C)2013 M2 COMMUNICATIONS